Interleukin-2 binds to ganglioside GD(1b)
| Autor: | Mepur H. Ravindranath, Daniel Soh, Donald L. Morton, Steven J. O'Day, Anton J. Bilchik, Alexandra Gonzales, Kevin Nishimoto, Wai-Yin Tam |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Interleukin 2
endocrine system Biophysics Matrix (biology) In Vitro Techniques Biochemistry law.invention law Gangliosides medicine Humans Molecular Biology Melanoma Immunoassay Ganglioside Binding Sites medicine.diagnostic_test Chemistry Cancer Cell Biology medicine.disease Molecular biology Recombinant Proteins Kinetics Ganglioside GD1b Immunology Recombinant DNA Interleukin-2 lipids (amino acids peptides and proteins) medicine.drug Protein Binding |
| Zdroj: | Biochemical and biophysical research communications. 283(2) |
| ISSN: | 0006-291X |
| Popis: | We have developed a solid matrix immunoassay to determine the binding of interleukin-2 (IL-2) to specific gangliosides. The assay establishes that recombinant human IL-2 binds to ganglioside GD(1b) but not to any other gangliosides (GM(1), GM(2), GM(3), GD(1a), GD(2), GD(3), and GT(1b)). The binding varies with the ratio of GD1b and IL-2. This assay enables distinguishing the nature of the sugar moiety of the ganglioside recognized by IL-2 and establishes the dosimetry of the ganglioside-IL-2 interaction. Since rIL-2 is administered systematically into stage IV melanoma patients, we have examined 45 tumor biopsies for GD(1b) content. The incidence of GD(1b) in tumor biopsies is 51%. We postulate that GD(1b) associated on the tumor or in the circulation of cancer patients may bind to rIL-2 and prevent the availability of rIL-2 to augment antitumor-immune response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect